|
Originally published In Press as doi:10.1074/jbc.M202783200 on May 23, 2002
J. Biol. Chem., Vol. 277, Issue 31, 28238-28246, August 2, 2002
Identification of Novel SH3 Domain Ligands for the Src
Family Kinase Hck
WISKOTT-ALDRICH SYNDROME PROTEIN (WASP), WASP-INTERACTING
PROTEIN (WIP), AND ELMO1*
Margaret Porter
Scott ,
Francesca
Zappacosta§,
Eun Young
Kim ,
Roland S.
Annan§, and
W. Todd
Miller ¶
From the Department of Physiology and Biophysics,
School of Medicine, State University of New York, Stony Brook, New
York 11794-8661 and the § Department of Computational and
Structural Sciences, GlaxoSmithKline Pharmaceuticals,
King of Prussia, Pennsylvania 19406
Received for publication, March 22, 2002
 |
ABSTRACT |
The importance of the SH3 domain of Hck in kinase
regulation, substrate phosphorylation, and ligand binding has been
established. However, few in vivo ligands are known for the
SH3 domain of Hck. In this study, we used mass spectrometry to identify
~25 potential binding partners for the SH3 domain of Hck from the
monocyte cell line U937. Two major interacting proteins were the actin
binding proteins Wiskott-Aldrich syndrome protein (WASP) and
WASP-interacting protein (WIP). We also focused on a novel interaction
between Hck and ELMO1, an 84-kDa protein that was recently identified as the mammalian ortholog of the Caenorhabditis elegans
gene, ced-12. In mammalian cells, ELMO1 interacts with
Dock180 as a component of the CrkII/Dock180/Rac pathway responsible for
phagocytosis and cell migration. Using purified proteins, we confirmed
that WASP-interacting protein and ELMO1 interact directly with the SH3
domain of Hck. We also show that Hck and ELMO1 interact in intact cells
and that ELMO1 is heavily tyrosine-phosphorylated in cells that
co-express Hck, suggesting that it is a substrate of Hck. The binding
of ELMO1 to Hck is specifically dependent on the interaction of a
polyproline motif with the SH3 domain of Hck. Our results suggest that
these proteins may be novel activators/effectors of Hck.
 |
INTRODUCTION |
The members of the Src family of nonreceptor tyrosine kinases
share a modular structure comprising unique SH3, SH2, and kinase catalytic domains (1-4). The enzymatic activity of Src family kinases
is tightly regulated by intramolecular interactions. The autoinhibited
state is maintained by two interactions, (i) an interaction between the
SH2 domain and a phosphorylated C-terminal tyrosine (Tyr-527) and (ii)
an interaction between the SH3 domain and a polyproline type II helix
in the SH2 kinase linker sequence (residues Pro-244-Trp-254) (5-7).
Src kinases can be potently activated by exogenous ligands for the SH3
and SH2 domains (8-11). These ligands disrupt the autoinhibitory
interactions, promote autophosphorylation at Tyr-416 within the
activation loop, and stimulate tyrosine kinase activity.
Binding of Src family kinases to cellular proteins can regulate kinase
activity by at least three mechanisms, (i) release of autoinhibitory
interactions as described above, (ii) relocalization of Src kinases to
sites of cellular action, and (iii) tethering the kinases to potential
substrates (1-3). These mechanisms often operate in combination, as is
seen when Src kinases are targeted to their substrates by SH3/SH2
domain interactions. Many cases have been described in which Src
kinases are recruited to their substrates via SH3 domain interactions.
For example, c-Src is known to associate with at least eight substrates
via direct binding of its SH3 domain to ligand binding motifs in the
substrates (2); well studied cases include Cas (12), FAK (13), and
AFAP-110 (14). The polyproline motifs in such substrates strongly
activate Src kinases by SH3 displacement and concomitantly tether the
substrate to the kinase, facilitating phosphorylation (13, 15, 16). The
dual role of the SH3 domain in substrate targeting is illustrated in
experiments with synthetic peptides, where phosphorylation of
substrates is greatly enhanced by the incorporation of an SH3 domain
ligand (17). These observations suggest that good substrates for
particular Src kinases might be discovered as SH3 domain ligands.
Hematopoietic cell kinase (Hck) is a Src family tyrosine kinase that is
expressed predominantly in granulocytic and monocytic cells (18, 19).
In granulocytes, Hck is found in a secretory granule-enriched fraction
and in a granule-free membrane fraction (20). The different subcellular
localizations of Hck are consistent with its proposed functional roles
in phagocytosis (21-24) and in receptor-mediated signaling (25-28).
In monocytes, Fc RII clustering leads to an array of
biological responses including phagocytosis, cell killing, secretion of
inflammatory mediators, and activation (25). Clustering of Fc RII
promotes activation of Hck and subsequent phosphorylation of the
receptor by direct association of Hck and Fc RII (26). Association of
Hck with an acidic region of the interleukin 6 receptor chain,
gp130, leads to Hck activation and cell proliferation (29).
There are several indications that Hck plays an important role in
integrin-mediated signal transduction. Neutrophils isolated from
Hck/Fgr double knockout mice are deficient in integrin-mediated respiratory burst and granule secretion (30-32). Integrin signaling in
polymorphonuclear leukocytes also activates Hck (33) and leads to
increased association of Hck and with the cytoskeleton (34). Another
role for Hck in actin rearrangement is suggested by the fact that Hck
is activated during E-selectin-mediated induction of monocyte
chemotaxis (35).
Hck has been implicated in a wide variety of signaling pathways in
hematopoietic cells. However, relatively few substrates or effectors of
Hck have been identified. One in vivo substrate for Hck, the
multidomain signaling protein Cbl, has been shown to interact with the
SH3 domain of Hck. As described above, we would expect that many of the
best cellular substrates for Hck would contain binding motifs for the
SH3 domain of the enzyme. The focus of this study was to identify and
characterize novel SH3 domain ligands for Hck. Two proteins that we
identified, Wiskott-Aldrich syndrome protein (WASP) and
WASP-interacting Protein (WIP), are known regulators of the actin
cytoskeleton (36, 37). A third Hck-interacting protein, ELMO1, has
recently been described as a component of signaling pathways that
regulate phagocytosis and cell migration (38). Hck has been implicated
in these pathways as well, suggesting that ELMO1 may represent an
important downstream substrate/effector of Hck.
 |
MATERIALS AND METHODS |
Expression and Purification of GST and GST-SH3(Hck)--
GST and
GST-SH3(Hck) were expressed in Escherichia coli NB42 cells.
Cells were lysed in a French pressure cell in buffer containing 50 mM HEPES, pH 7.4, 100 mM NaCl, 100 mM EDTA, 1% Triton X-100, 10% glycerol, and protease
inhibitors (5 mg/liter of aprotinin, 5 mg/liter leupeptin, 0.1 mM phenylmethylsulfonyl fluoride). Cell lysates were
centrifuged, and the supernatants were added to glutathione-agarose (Molecular Probes). After a 1-h incubation at 4 °C the beads were washed 5 times with buffer containing 50 mM HEPES, pH 7.4, and 100 mM EDTA. Glutathione-agarose with immobilized GST
or GST-SH3 was used directly in ligand binding experiments. The
concentration of GST or GST-SH3 on the beads was determined by treating
50 µl of beads with 20 mM glutathione in 50 mM Tris, pH 8. The total amount of protein eluted was
determined by the Bradford method (Bio-Rad) and divided by 50 µl to
calculate the total concentration on the beads. Control beads were
added to dilute the protein concentration to 1 mg/ml.
Identification of Hck-SH3 Domain-associated Proteins--
U937
cells were maintained in RPMI 1640 medium supplemented with 5% fetal
bovine serum. Before the pull-down experiment, 800 ml of U937 cells at
a density of 106 cells/ml were treated with 10 ng/ml
phorbol 12-myristate 13-acetate. After 48 h, cells were harvested
and then washed 2× with phosphate-buffered saline. Cells were lysed
for 30 min with rocking in 4 ml of lysis buffer containing 1% Triton
X-100, 10 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA, 2 mM sodium orthovanadate, and
protease inhibitors (5 mg/liter aprotinin, 5 mg/liter leupeptin, 0.1 mM phenylmethylsulfonyl fluoride). After centrifugation, a
1-ml portion of this lysate (containing 5 mg of protein) was added to
50 µl of glutathione-agarose containing 50 µg of GST-SH3. The
remaining portion (3 ml, containing 15 mg protein) was added to 50 µl
of glutathione-agarose containing 50 µg of GST. Beads and lysate were
rocked 2 h at 4 °C and then washed 5 times with 10 ml of lysis
buffer. Bound proteins were eluted in 50 µl of gel loading buffer by boiling.
Proteins that eluted from the GST-SH3(Hck) affinity column were
separated by one-dimensional SDS-PAGE and visualized with colloidal
Coomassie stain. Protein bands specific to the Hck-SH3 pull-downs were
excised and digested with trypsin as previously described (39).
According to the intensity of the Coomassie band, 1/20 to1/3 of each
unfractionated tryptic digest was analyzed by on-line liquid
chromatography-electrospray tandem mass spectrometry using a
micro-column (75 µm × 10 cm, 3-µm particles) reverse phase HPLC1 interfaced to an LCQ
Deca ion trap mass spectrometer. Electrospray tandem mass
spectrometry-based sequencing was performed on line in a
data-dependent manner (40) as peptides eluted from the HPLC. Uninterpreted spectra were searched for protein matches against a
non-redundant protein data base using the program Mascot (41).
Similar experiments were carried out to measure binding between
immobilized GST-SH3(Hck) and purified proteins or proteins in Chinese
hamster ovary (CHO) cell lysates, with the exception that binding
reactions contained 10 µl of glutathione-agarose beads. In some
experiments, various concentrations of polyproline-containing peptides
were added together with the immobilized SH3 domain.
Protein Expression and Purification--
C-terminally
phosphorylated wild type Hck, WIP, and ELMO1 were produced in
Spodoptera frugiperda (Sf9) cells using baculovirus expression vectors. Hck was expressed and purified as described previously (16). The cDNA for WIP was the kind gift of Dr.
Narayanaswamy Ramesh (Harvard Medical School). The WIP-coding sequence
was amplified by PCR and subcloned into the baculovirus expression
vector pFastBac-Htb (Invitrogen). The cDNA for ELMO1 was obtained
as clone DKFZp434B0819 from the German Cancer Research Center. We
amplified the 2184-base pair DNA sequence by PCR and ligated it as an
EcoRI/KpnI fragment into the baculovirus
expression vector pFastBac-Htb.
WIP and ELMO1 were expressed in Sf9 cells using the Invitrogen
Bac-to-Bac system. Cells expressing His-tagged WIP and ELMO1 were lysed
in a French pressure cell in buffer A (20 mM Tris, pH 8.5, 10% glycerol, 5 mM -mercaptoethanol) containing
protease inhibitors (5 mg/liter of aprotinin, 5 mg/liter leupeptin, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM
EDTA). Cell lysate was diluted to 200 ml with column loading buffer (20 mM Tris, pH 8.5, 5% glycerol, 5 mM
-mercaptoethanol, 1 M NaCl, and 20 mM
imidazole) and centrifuged. Lysate was passed over a 5-ml nickel nitrilotriacetic acid Superflow column (Qiagen). WIP and ELMO1 were
eluted with 100 mM imidazole. The concentration of ELMO1 and WIP were determined using the Bradford method (Bio-Rad).
Synthetic Peptides--
The substrate peptide for the coupled
assay (AEEEIYGEFEAKKKKG (42)) was prepared by solid phase synthesis on
an Applied Biosystems automated 431A Peptide Synthesizer. It was
purified by reverse phase high pressure liquid chromatography and
characterized by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry. The polyproline-containing peptide
(DFPLGPPPPLPPRATPSR (43)) was the generous gift of Dean Edwards
(University of Colorado).
Protein Kinase Assay--
Kinase assays were performed by a
coupled spectrophotometric assay (44). In this assay, the production of
ADP is coupled to the oxidation of NADH measured as a reduction in
absorbance at 340 nm. All experiments were carried out at 30 °C.
Reactions were performed in buffer containing 100 mM Tris,
pH 7.5, 10 mM MgCl2, 1 mM
phosphoenolpyruvate, 0.28 mM NADH, 89 units/ml pyruvate kinase, and 124 units/ml lactate dehydrogenase. The assays contained 400 µM peptide substrate and 10 nM Hck.
Expression in CHO Cells and Immunoprecipitation
Experiments--
The ELMO1 cDNA was subcloned into two expression
vectors to generate epitope-tagged versions of ELMO1 for mammalian
expression, 1) pEF1/V5-HisA (Invitrogen) for a C-terminal V5 tag and 2)
pCM45 (gift of Steve Lang and Pat Hearing, SUNY Stony Brook) for an N-terminal M45 tag. Full-length human Hck cDNA was subcloned into plasmid pCDNA6 (Invitrogen). Two 150-mm tissue culture plates were
transfected for each condition tested. Transfections were carried out
with 3.5 µl of TransIt (Panvera)/µg of DNA according to the
manufacturer's protocol. After 40-48 h, cells from the two plates
were combined and washed 2× in phosphate-buffered saline. Cells were
lysed in lysis buffer (1% Triton X-100, 10 mM Tris, pH
7.5, 150 mM NaCl, 5 mM EDTA, 2 mM
vanadate, and protease inhibitors) and clarified by centrifugation, and
the protein concentration was determined. An equal amount (between 1 and 5 mg) of total cell protein was diluted to 1 ml for each reaction
and precleared with 50 µl of protein A- or G-Sepharose beads for
1 h at 4 °C with rocking. After pre-clearing, 2 µg of
appropriate antibody (or 15 µl of serum containing M45 antibody) or
control antibody was added to lysate and incubated overnight at 4 °C
with rocking. Antibodies used were mouse anti-M45 (P. Hearing, SUNY
Stony Brook), mouse anti-Hck (Transduction Laboratories), rabbit
anti-Hck (Santa Cruz), rabbit anti-WIP (a gift of Dr. Narayanaswamy
Ramesh, Harvard Medical School), rabbit anti-WASP (Santa Cruz), and
mouse anti-V5 (Invitrogen). Antibody-protein complexes were collected
with 50 µl of protein A- or G-Sepharose beads for 1 h at 4 °C
with rocking. The beads were washed 5 times in lysis buffer and boiled
in 40 µl of gel loading buffer. After separation by SDS-PAGE,
proteins were transferred to PVDF membranes. Incubation with primary
antibody was carried out according to the manufacturer's protocol.
After washing, the appropriate horseradish peroxidase-conjugated
secondary antibody was added, and proteins were detected using the
enhanced chemiluminescent detection kit (Amersham Biosciences).
 |
RESULTS |
Screening for Binding Partners of the SH3 Domain of Hck--
Hck
is expressed predominantly in myeloid cells such as monocytes (18).
Furthermore, differentiation of monocytes to macrophages is associated
with increased Hck expression and activity (18). We reasoned that the
more differentiated phenotype would also be accompanied by increases in
specific binding complexes between Hck and other signaling proteins.
Therefore, we treated U937 monocytes with phorbol 12-myristate
13-acetate for 48 h to induce the cells to differentiate to a more
macrophage-like phenotype (45). Clarified lysate from these cells was
added to glutathione-agarose beads containing immobilized GST-SH3(Hck).
As a control, 3-fold more U937 lysate was added to beads containing GST
alone. After extensive washing, bound proteins were eluted by boiling
in Laemmli buffer and then subjected to SDS-PAGE and visualized with
colloidal Coomassie stain (Fig. 1). All
visible bands were excised from the GST-SH3(Hck) lane. Bands in the
control lane having similar molecular weight and intensity as bands in
the GST-SH3(Hck) lane were also excised. The proteins in the bands were
reduced, alkylated, and digested overnight with trypsin. The tryptic
digests were analyzed by on-line liquid chromatography-electrospray
tandem mass spectrometry, and the uninterpreted data was searched
against the non-redundant protein data base using the program
Mascot (41). Proteins identified in the GST-SH3(Hck) lane but not the
control lane are presented in Table
I. The table also briefly summarizes what
is known about the biological function of the interacting proteins and
lists whether they have previously been shown to bind to any Src family kinase.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 1.
Identification of proteins in U937 cell
lysates that bind to GST-SH3(Hck). Phorbol 12-myristate
13-acetate-treated U937 cells (800 × 106) were lysed
in a volume of 4 ml. A 3-ml portion of the lysate was added to
glutathione-agarose beads containing 50 µg of GST, and the remaining
1 ml was added to beads containing 50 µg of GST-SH3(Hck). After 30 min of incubation, beads were washed 5 times in lysis buffer, and bound
proteins were eluted by boiling in Laemmli buffer. Bound proteins were
separated by SDS-PAGE. Bands from SDS-PAGE gel were reduced, alkylated,
and digested overnight with trypsin. Tryptic digests were analyzed by
on-line liquid chromatography-electrospray tandem mass spectrometry.
The sequences were searched against the protein data base. Selected
proteins are indicated to the right of the gel, and the complete list
of proteins identified is given in Table I.
|
|
Two proteins have previously been shown to interact with the SH3 domain
of Hck, Cbl (46) and Sam-68 (47). Our approach identified both of these
binding partners (Fig. 1, Table I). In multiple experiments, the most
intensely staining band was in the range of 50-55 kilodaltons (Fig.
1). The components of this band were found to be the actin-associated
proteins WASP and WIP. WASP has previously been shown to interact with
the SH3 domains of Src, Fyn, and Fgr (48, 49), whereas WIP has not previously been described to bind to Src kinases. Both of these proteins contain Pro-rich regions that would be predicted to bind to
SH3 domains (Fig. 2). We confirmed the
association of WIP and WASP with the SH3 domain of Hck in phorbol
12-myristate 13-acetate-treated U937 cells as well as in THP-1 human
leukemia cells. Cell lysates were incubated with immobilized
GST-SH3(Hck) or GST as a control, then bound proteins were separated by
SDS-PAGE and detected by Western blotting with anti-WASP or anti-WIP
antibodies. In both cell lines, WIP and WASP were associated with
GST-SH3(Hck), and they did not associate with GST alone (Fig.
3).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
The domain structures of WASP, WIP, and
ELMO1 (36-38). GBD, GTPase binding domain;
CHS, cofilin homology sequence; WH1 and
WH2, WASP homology domains 1 and 2; ABM-2,
actin-based motility sequence 2.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Identification of WASP and WIP in U937 and
THP-1 cells. Pull-down reactions were performed as in the legend
to Fig. 1, except equal amounts of U937 and THP-1 lysates were added to
both GST and GST-SH3-containing beads. After separation by SDS-PAGE,
proteins were transferred to PVDF membranes and detected by Western
blotting using either anti-N-WASP antibody (Santa Cruz) or anti-WIP
antibody (a gift from N. Ramesh, Harvard Medical School).
|
|
Our initial Hck SH3 domain pull-down experiments were performed on U937
whole cell lysates. The interacting proteins identified such as WASP
and WIP may interact directly with the SH3 domain via polyproline
motifs or, alternatively, might interact indirectly via other proteins
present in the lysates. WASP has previously been shown to interact
directly with Src kinase SH3 domains (48, 50). To show that the binding
between WIP and the SH3 domain of Hck was direct, we carried out a
binding experiment using purified protein components. We produced WIP
in Sf9 cells by infecting cells with a recombinant baculovirus
encoding His-tagged WIP. After purification of WIP on nickel
nitrilotriacetic acid resin, we mixed various amounts of WIP with
immobilized GST-SH3(Hck). After washing, we eluted the bound proteins
and analyzed them by SDS-PAGE followed by Western blotting with
anti-WIP antibody. WIP was able to form a complex with the SH3 domain
of Hck in this experiment (Fig.
4A).

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 4.
A, in vitro
association between WIP and HckSH3. Various amounts of purified WIP
were added to pull-down reactions containing 10 µl of immobilized
GST-HckSH3 (first four lanes). After washing and elution,
bound proteins were separated by SDS-PAGE, transferred to PVDF
membranes, and visualized by Western blotting using anti-His-tag
antibody (Santa Cruz). In the lane marked WIP 2 µg of
purified WIP was loaded directly onto the gel. In the last
lane, results are shown from a control pull-down reaction with GST
using 30 µg of purified WIP. B, activation of
down-regulated Hck by WIP. Various amounts of purified WIP were added
to kinase reactions containing down-regulated Hck and a synthetic
peptide substrate. Phosphorylation of the peptide substrate was
measured by a spectrophotometric assay. The fold activation is
expressed relative to a control without WIP.
|
|
Binding of a polyproline-containing ligand to the SH3 domain of Hck can
lead to kinase activation (8). To test whether WIP could activate Hck
in vitro, we expressed and purified the down-regulated form
of Hck from Sf9 cells. We added increasing concentrations of
purified WIP to Hck and followed kinase activity using a continuous
spectrophotometric assay. Micromolar concentrations of WIP activated
Hck under these conditions (Fig. 4B).
ELMO1 Binds Directly to the SH3 Domain of Hck via Polyproline
Interactions--
Among the novel binding partners for Hck we
discovered was an 85-kDa protein that matched the sequence of a
hypothetical protein identified in an effort to analyze 500 novel human
cDNAs (51). We obtained the clone from the German Cancer Research Center. While this work was in progress, the protein was discovered in
a different context and designated ELMO1 (Table I). ELMO1 is an 84-kDa
protein that was identified as the mammalian ortholog of the
Caenorhabditis elegans gene, ced-12 (38). CED-12
is required for the engulfment of dying cells and for cell migration
(38). In mammalian cells, ELMO1 interacts with Dock180 as part of the CrkII/Dock180/Rac pathway responsible for phagocytosis and cell migration (38). The amino acid sequence of ELMO1 shows little homology
to other proteins in the data base, with the exception of the C
terminus, which contains a putative pleckstrin homology (PH) domain and
a Pro-rich sequence (Fig. 2). In the next series of experiments, we
focused in more detail on the interaction between ELMO1 and the SH3
domain of Hck.
To determine whether ELMO1 binds directly to the SH3 domain of Hck, we
carried out binding experiments with purified proteins. We expressed
ELMO1 as a His-tagged protein using the Sf9/baculovirus system.
Chromatography on nickel nitrilotriacetic acid affinity resin yielded a
highly purified preparation of ELMO1 (data not shown). We then mixed
various amounts of ELMO1 with immobilized Hck SH3 domain. After
washing, we eluted the bound protein and analyzed by SDS-PAGE followed
by Western blotting with anti-His-tag antibody. ELMO1 bound to the Hck
SH3 domain in these experiments (Fig. 5).
We conclude that ELMO1 and Hck can interact directly in the absence of
any other binding partners. Furthermore, the interaction between ELMO1
and the SH3 domain of Hck was reduced when experiments were carried out
in the presence of a polyproline-containing peptide that binds to Src
kinase SH3 domains (data not shown; also see Fig. 7).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 5.
In vitro association between ELMO1
and Hck. The indicated amounts of purified ELMO1 were added to
pull-down reactions containing 10 µl of immobilized GST-HckSH3. In
the right-hand lane, results are shown from a control GST
pull-down reaction with 10 µg of ELMO1. After washing and elution,
bound proteins were separated by SDS-PAGE and visualized by Coomassie
Blue staining. In the lane marked ELMO1, 1 µg of purified
ELMO1 was loaded directly onto the gel.
|
|
ELMO1 Associates with Hck in Intact Cells--
We constructed
mammalian expression vectors for ELMO1 that contained either a
C-terminal V5 epitope tag or an N-terminal M45 epitope tag. To
determine whether Hck and ELMO1 interact in intact cells, we
co-expressed Hck and V5 epitope-tagged ELMO1 in CHO cells. We isolated
Hck from CHO cell lysates by immunoprecipitation and analyzed the
co-immunoprecipitating proteins by anti-V5 Western blotting. V5-ELMO1
co-immunoprecipitated with Hck in these experiments but was not
detected in control immunoprecipitation reactions (Fig.
6). We obtained similar results when Hck
and ELMO1 were overexpressed in Cos-7 cells (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 6.
Association of Hck and ELMO1 in CHO
cells. Pre-cleared lysate from cells co-transfected with either
Hck and empty vector or Hck and V5-tagged ELMO1 was immunoprecipitated
(IP) using 2 µg of Hck or control (C) rabbit
antibody (see "Materials and Methods"). Proteins in the
immunoprecipitates were separated by SDS-PAGE, transferred to PVDF
membranes, and analyzed by Western blotting with anti-V5 antibody.
Bottom panel, the membrane was stripped and reprobed with
anti-Hck antibody.
|
|
Next, we confirmed that the Hck-ELMO1 association was dependent on
polyproline interactions. For these experiments, we expressed ELMO1 in
CHO cells with an N-terminal M45 epitope tag. We then incubated CHO
cell lysates with immobilized GST-SH3(Hck). To individual pull-down
reactions we added increasing amounts of a polyproline peptide, which
binds to the SH3 domain of Hck (43). Binding of ELMO1 to the SH3 domain
of Hck was nearly abolished in the presence of 500 µM
peptide (Fig. 7). This suggests that the
primary mode of interaction of ELMO1 with Hck is via the interaction of the SH3 domain with the polyproline region of ELMO1.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 7.
The association of ELMO1 with Hck is
abrogated by addition of polyproline peptide. CHO cells were
transfected with M45-ELMO1. Equal amounts of lysate from these cells
were divided among tubes containing either GST-SH3(Hck) or GST
immobilized on glutathione-agarose beads. Increasing amounts of a
polyproline-containing peptide (43) were incubated with lysate in
reactions with GST-SH3(Hck). Beads were washed and eluted by boiling in
gel-loading buffer. After separation by SDS-PAGE and transfer to PVDF,
M45-ELMO1 was detected by immunoblotting with an anti-M45 antibody.
Right lane, lysate loaded directly onto the gel.
|
|
We carried out experiments to test for tyrosine phosphorylation of
ELMO1 in cells overexpressing Hck. We expressed M45-tagged ELMO1 in the
presence or absence of Hck, isolated ELMO1 by immunoprecipitation, then
carried out anti-phosphotyrosine immunoblotting. ELMO1 is heavily
tyrosine-phosphorylated in cells co-expressing Hck but not in cells
expressing ELMO1 alone (Fig. 8). These
results show that Hck either phosphorylates ELMO1 directly or activates
a pathway leading to tyrosine phosphorylation of ELMO1.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 8.
Phosphorylation of ELMO1 by Hck in CHO
cells. Cells were transfected with Hck plus empty vector (M45),
ELMO1 plus empty vector (pCDNA6), or Hck plus M45-ELMO1. Lysates
from each of these cells were divided into two equal portions, and
immunoprecipitation (IP) reactions were carried out using 2 µg of either M45 or control (C) mouse antibody.
Immunoprecipitated proteins were separated by SDS-PAGE and transferred
to PVDF membranes. A, top panel, detection with
anti-phosphotyrosine antibody (4G10). Bottom panel, the
membrane was stripped and reprobed with anti-M45 antibody.
B, expression of Hck and ELMO1 in CHO cell lysates.
Lane 1, untransfected CHO cells. Lane 2, cells
expressing Hck. Lane 3, cells expressing ELMO1. Lane
4, cells expressing Hck and ELMO1.
|
|
 |
DISCUSSION |
Although Hck is known to play an important role in the function of
hematopoietic cells, few in vivo binding partners for Hck have been discovered. Because Src kinases form stable complexes with
many preferred substrates via their SH3 domains, we performed a screen
using the SH3 domain of Hck to isolate proteins from U937 monocytic
cells. We then subjected proteins that bound to the SH3 domain of Hck
to sequencing by mass spectrometry. We identified proteins known to
bind to Hck (Cbl and Sam68), proteins known to interact with other Src
family kinases (Sos, ASAP1, heterogeneous nuclear ribonucleoprotein K,
CMS/CD2-associated protein, p85, and SLP-76), and a large number of
proteins that have not previously been reported to interact with Src
kinases (Table I). Unlike yeast two-hybrid experiments, which detect
primarily direct interactions, these experiments can also detect
secondary and long range interactions. Thus, some of the identified
proteins may be components of Hck signaling complexes that do not
contact Hck directly.
Because Hck is involved in integrin-mediated signal transduction in
macrophages, we expected that actin-associated proteins might be
binding partners for Hck. Two prominent bands that associated with the
SH3 domain of Hck were WASP and WIP (Fig. 1). WIP and WASP are both
well characterized as proteins required for actin polymerization (36,
37). WASP was identified as the gene responsible for the
Wiskott-Aldrich syndrome, a disease characterized by decreased size and
number of platelets and lymphocytes (37). WIP was originally cloned
from a human lymphoma T cell line library as a WASP-interacting protein
(52). WIP is extremely glycine- and proline-rich and is known to
regulate actin assembly in association with WASP (53). Although WIP and
WASP are known to associate directly with each other, the data
presented here along with data in the literature suggest they both can
interact with SH3 domains in an independent manner. WIP and WASP both
have multiple copies of a polyproline-containing SH3 domain ligand
motif (Fig. 2). WASP had previously been shown to bind and activate the
Src family kinase Fyn in vitro (48, 49). WIP has not
previously been shown to interact with Src family tyrosine kinases. We
expressed and purified WIP and show that it binds and activates Hck
in vitro (Fig. 4).
WASP may be a substrate for Hck in vivo. One previous report
showed that WASP was a substrate for the Src family kinase, Lyn, in
response to aggregation of the high affinity IgE receptor at the
surface of mast cells (54). The site(s) phosphorylated by Lyn in this
study was not identified. The role of WASP phosphorylation is not
clear, but phosphorylation may be involved in regulating conformational
changes in WASP. WASP has two dramatically different conformations
(55). In the autoinhibited conformation, the GTPase binding domain
interacts with the C-terminal region. Binding of the Rho family GTPase,
Cdc42, can relieve this autoinhibition and release the C terminus to
interact with actin regulatory machinery (56). Phosphorylation may play
a role in stabilizing one or both of the conformations (55). We have
confirmed that WASP and Hck interact when overexpressed in CHO
cells.2 Preliminary
experiments in this model system also indicate that WASP is
tyrosine-phosphorylated in Hck-expressing CHO cells.
One of the binding partners for the SH3 domain of Hck that we
identified in our screen was a previously unidentified protein of 84 kDa (Table I). While this work was in progress, the 84-kDa protein was
identified in another context and designated ELMO1 (38, 57, 58). ELMO1
is the mammalian ortholog of the C. elegans gene,
ced-12. CED-12 is required for the engulfment of dying cells
and cell migration. In mammalian cells, ELMO1 interacts with Dock180 as
part of the CrkII/Dock180/Rac pathway responsible for phagocytosis and
cell migration (38, 57, 58). ELMO1 is ubiquitously expressed, although
its expression was highest in the spleen, an organ rich in immune cells
(38). ELMO1 has a PH domain and a polyproline sequence motif at its C
terminus (Fig. 2). Our experiments suggest that binding between Hck and ELMO1 depends on SH3-polyproline interactions (Figs. 5 and 7). The
remainder of the amino acid sequence of ELMO1 does not show significant
homology to other proteins in the data base except for a short region
with homology to the Drosophila voltage-gated K+ channel Shab.
The importance of Hck in cell migration (28, 30, 35, 59, 60) and
phagocytosis (21-24) is well established. Macrophages from
Hck-deficient mice show impaired phagocytosis (61). There are a number
of points at which Hck could influence the
CrkII/Dock180/ELMO1-signaling pathway. Integrin receptors are important
for the phagocytosis of apoptotic cells. Integrin signaling has been
shown to recruit the
p130cas·CrkII·Dock180 molecular
complex, which in turn triggers Rac1 activation and phagosome formation
(62). In these studies, an unidentified tyrosine kinase was necessary
for recruitment of the Cas·CrkII·Dock180 complex. ELMO1 is likely
to be recruited as a component of this complex, and Hck could be
involved in either the assembly or disassembly of the complex.
Hck is also known to be involved in Fc RII-mediated
phagocytosis in monocytes, raising the possibility that a
CrkII·Dock180·ELMO1 complex plays a role in this process. ELMO1 may
be an important factor in activating Hck signaling in the cytoplasm
after Fc RII receptor stimulation. We demonstrated that ELMO1 is
tyrosine-phosphorylated in Hck-expressing cells (Fig. 8). ELMO1 might
therefore act as a downstream substrate of Hck in this signaling
pathway, and phosphorylation of ELMO1 by Hck might modulate the ability
of ELMO1 to cause changes in cell motility or phagocytosis.
 |
ACKNOWLEDGEMENTS |
We thank Narayanaswamy Ramesh (Harvard
Medical School) for the WIP cDNA and for anti-WIP antibody. We
thank Patrick Hearing and Steve Lang (SUNY Stony Brook) for vector
pCM45 and the anti-M45 antibody. We are also grateful to Dean
Edwards (University of Colorado) for the polyproline-containing
peptide. We thank Noriko Yokoyama (SUNY Stony Brook) for help with the
binding assays and Svetlana Favelyukis and Patricia Pellicena (SUNY
Stony Brook) for assistance with the baculovirus expression of WIP.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant CA58530 (to W. T. M.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of
Physiology and Biophysics, Basic Science Tower, T-6, School of
Medicine, SUNY at Stony Brook, Stony Brook, NY 11794-8661. Tel.:
631-444-3533; Fax: 631-444-3432; E-mail:
miller@physiology.pnb.sunysb.edu.
Published, JBC Papers in Press, May 23, 2002, DOI 10.1074/jbc.M202783200
2
M. P. Scott and W. T. Miller,
unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
HPLC, high pressure
liquid chromatography;
CHO, Chinese hamster ovary;
WIP, WASP-interacting protein;
WASP, Wiskott-Aldrich syndrome protein;
PVDF, polyvinylidene difluoride;
GST, glutathione S-transferase.
 |
REFERENCES |
| 1.
|
Bjorge, J. D.,
Jakymiw, A.,
and Fujita, D. J.
(2000)
Oncogene
19,
5620-5635[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Brown, M. T.,
and Cooper, J. A.
(1996)
Biochim. Biophys. Acta
1287,
121-149[Medline]
[Order article via Infotrieve]
|
| 3.
|
Schwartzberg, P. L.
(1998)
Oncogene
17,
1463-1468[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Thomas, S. M.,
and Brugge, J. S.
(1997)
Annu. Rev. Cell Dev. Biol.
13,
513-609[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Sicheri, F.,
Moarefi, I.,
and Kuriyan, J.
(1997)
Nature
385,
602-609[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Xu, W.,
Harrison, S. C.,
and Eck, M. J.
(1997)
Nature
385,
595-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Williams, J. C.,
Weijland, A.,
Gonfloni, S.,
Thompson, A.,
Courtneidge, S. A.,
Superti-Furga, G.,
and Wierenga, R. K.
(1997)
J. Mol. Biol.
274,
757-775[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Moarefi, I.,
LaFevre-Bernt, M.,
Sicheri, F.,
Huse, M.,
Lee, C. H.,
Kuriyan, J.,
and Miller, W. T.
(1997)
Nature
385,
650-653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Briggs, S. D.,
Sharkey, M.,
Stevenson, M.,
and Smithgall, T. E.
(1997)
J. Biol. Chem.
272,
17899-17902[Abstract/Free Full Text]
|
| 10.
|
Alexandropoulos, K.,
and Baltimore, D.
(1996)
Genes Dev.
10,
1341-1355[Abstract/Free Full Text]
|
| 11.
|
Liu, X.,
Brodeur, S. R.,
Gish, G.,
Songyang, Z.,
Cantley, L. C.,
Laudano, A. P.,
and Pawson, T.
(1993)
Oncogene
8,
1119-1126[Medline]
[Order article via Infotrieve]
|
| 12.
|
Nakamoto, T.,
Sakai, R.,
Ozawa, K.,
Yazaki, Y.,
and Hirai, H.
(1996)
J. Biol. Chem.
271,
8959-8965[Abstract/Free Full Text]
|
| 13.
|
Thomas, J. W.,
Ellis, B.,
Boerner, R. J.,
Knight, W. B.,
White, G. C., II,
and Schaller, M. D.
(1998)
J. Biol. Chem.
273,
577-583[Abstract/Free Full Text]
|
| 14.
|
Guappone, A. C.,
and Flynn, D. C.
(1997)
Mol. Cell Biochem.
175,
243-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Pellicena, P.,
and Miller, W. T.
(2001)
J. Biol. Chem.
276,
28190-28196[Abstract/Free Full Text]
|
| 16.
|
Porter, M.,
Schindler, T.,
Kuriyan, J.,
and Miller, W. T.
(2000)
J. Biol. Chem.
275,
2721-2726[Abstract/Free Full Text]
|
| 17.
|
Scott, M. P.,
and Miller, W. T.
(2000)
Biochemistry
39,
14531-14537[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Quintrell, N.,
Lebo, R.,
Varmus, H.,
Bishop, J. M.,
Pettenati, M. J., Le,
Beau, M. M.,
Diaz, M. O.,
and Rowley, J. D.
(1987)
Mol. Cell. Biol.
7,
2267-2275[Abstract/Free Full Text]
|
| 19.
|
Ziegler, S. F.,
Marth, J. D.,
Lewis, D. B.,
and Perlmutter, R. M.
(1987)
Mol. Cell. Biol.
7,
2276-2285[Abstract/Free Full Text]
|
| 20.
|
Welch, H.,
and Maridonneau-Parini, I.
(1997)
J. Biol. Chem.
272,
102-109[Abstract/Free Full Text]
|
| 21.
|
Kedzierska, K.,
Vardaxis, N. J.,
Jaworowski, A.,
and Crowe, S. M.
(2001)
J. Leukocyte Biol.
70,
322-328[Abstract/Free Full Text]
|
| 22.
|
Suzuki, T.,
Kono, H.,
Hirose, N.,
Okada, M.,
Yamamoto, T.,
Yamamoto, K.,
and Honda, Z.
(2000)
J. Immunol.
165,
473-482[Abstract/Free Full Text]
|
| 23.
|
Majeed, M.,
Caveggion, E.,
Lowell, C. A.,
and Berton, G.
(2001)
J. Leukocyte Biol.
70,
801-811[Abstract/Free Full Text]
|
| 24.
|
N'Diaye, E. N.,
Darzacq, X.,
Astarie-Dequeker, C.,
Daffe, M.,
Calafat, J.,
and Maridonneau-Parini, I.
(1998)
J. Immunol.
161,
4983-4991[Abstract/Free Full Text]
|
| 25.
|
Daeron, M.
(1997)
Annu. Rev. Immunol.
15,
203-234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Ghazizadeh, S.,
Bolen, J. B.,
and Fleit, H. B.
(1994)
J. Biol. Chem.
269,
8878-8884[Abstract/Free Full Text]
|
| 27.
|
Mocsai, A.,
Jakus, Z.,
Vantus, T.,
Berton, G.,
Lowell, C. A.,
and Ligeti, E.
(2000)
J. Immunol.
164,
4321-4331[Abstract/Free Full Text]
|
| 28.
|
Chiaradonna, F.,
Fontana, L.,
Iavarone, C.,
Carriero, M. V.,
Scholz, G.,
Barone, M. V.,
and Stoppelli, M. P.
(1999)
EMBO J.
18,
3013-3023[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Schaeffer, M.,
Schneiderbauer, M.,
Weidler, S.,
Tavares, R.,
Warmuth, M.,
de Vos, G.,
and Hallek, M.
(2001)
Mol. Cell. Biol.
21,
8068-8081[Abstract/Free Full Text]
|
| 30.
|
Suen, P. W.,
Ilic, D.,
Caveggion, E.,
Berton, G.,
Damsky, C. H.,
and Lowell, C. A.
(1999)
J. Cell Sci.
112,
4067-4078[Abstract]
|
| 31.
|
Lowell, C. A.,
Fumagalli, L.,
and Berton, G.
(1996)
J. Cell Biol.
133,
895-910[Abstract/Free Full Text]
|
| 32.
|
Mocsai, A.,
Ligeti, E.,
Lowell, C. A.,
and Berton, G.
(1999)
J. Immunol.
162,
1120-1126[Abstract/Free Full Text]
|
| 33.
|
Piccardoni, P.,
Sideri, R.,
Manarini, S.,
Piccoli, A.,
Martelli, N.,
de Gaetano, G.,
Cerletti, C.,
and Evangelista, V.
(2001)
Blood
98,
108-116[Abstract/Free Full Text]
|
| 34.
|
Nair, K. S.,
and Zingde, S. M.
(2001)
Cell. Immunol.
208,
96-106[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Kumar, P.,
Hosaka, S.,
and Koch, A. E.
(2001)
J. Biol. Chem.
276,
21039-21045[Abstract/Free Full Text]
|
| 36.
|
Zigmond, S. H.
(2000)
J. Cell Biol.
150,
117-120
|
| 37.
|
Ramesh, N.,
Anton, I. M.,
Martinez-Quiles, N.,
and Geha, R. S.
(1999)
Trends Cell Biol.
9,
15-19[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Gumienny, T. L.,
Brugnera, E.,
Tosello-Trampont, A. C.,
Kinchen, J. M.,
Haney, L. B.,
Nishiwaki, K.,
Walk, S. F.,
Nemergut, M. E.,
Macara, I. G.,
Francis, R.,
Schedl, T.,
Qin, Y.,
Van Aelst, L.,
Hengartner, M. O.,
and Ravichandran, K. S.
(2001)
Cell
107,
27-41[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Joyal, J. L.,
Annan, R. S., Ho, Y. D.,
Huddleston, M. E.,
Carr, S. A.,
Hart, M. J.,
and Sacks, D. B.
(1997)
J. Biol. Chem.
272,
15419-15425[Abstract/Free Full Text]
|
| 40.
|
McCormack, A. L.,
Schieltz, D. M.,
Goode, B.,
Yang, S.,
Barnes, G.,
Drubin, D.,
and Yates, J. R., III
(1997)
Anal. Chem.
69,
767-776[Medline]
[Order article via Infotrieve]
|
| 41.
|
Perkins, D. N.,
Pappin, D. J.,
Creasy, D. M.,
and Cottrell, J. S.
(1999)
Electrophoresis
20,
3551-3567[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Songyang, Z.,
Carraway, K. L., III,
Eck, M. J.,
Harrison, S. C.,
Feldman, R. A.,
Mohammadi, M.,
Schlessinger, J.,
Hubbard, S. R.,
Smith, D. P.,
Eng, C.,
Lorenzo, M. J.,
Poner, B. A. J.,
Mayer, B. J.,
and Cantley, L. C.
(1995)
Nature
373,
536-539[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Boonyaratanakornkit, V.,
Scott, M. P.,
Ribon, V.,
Sherman, L.,
Anderson, S. M.,
Maller, J. L.,
Miller, W. T.,
and Edwards, D. P.
(2001)
Mol. Cell
8,
269-280[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Barker, S. C.,
Kassel, D. B.,
Weigl, D.,
Huang, X.,
Luther, M. A.,
and Knight, W. B.
(1995)
Biochemistry
34,
14843-14851[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Schwende, H.,
Fitzke, E.,
Ambs, P.,
and Dieter, P.
(1996)
J. Leukocyte Biol.
59,
555-561[Abstract]
|
| 46.
|
Howlett, C. J.,
Bisson, S. A.,
Resek, M. E.,
Tigley, A. W.,
and Robbins, S. M.
(1999)
Biochem. Biophys. Res. Commun.
257,
129-138[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Taylor, S. J.,
Anafi, M.,
Pawson, T.,
and Shalloway, D.
(1995)
J. Biol. Chem.
270,
10120-10124[Abstract/Free Full Text]
|
| 48.
|
Banin, S.,
Truong, O.,
Katz, D. R.,
Waterfield, M. D.,
Brickell, P. M.,
and Gout, I.
(1996)
Curr. Biol.
6,
981-988[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Banin, S.,
Gout, I.,
and Brickell, P.
(1999)
Mol. Biol. Rep.
26,
173-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Finan, P. M.,
Soames, C. J.,
Wilson, L.,
Nelson, D. L.,
Stewart, D. M.,
Truong, O.,
Hsuan, J. J.,
and Kellie, S.
(1996)
J. Biol. Chem.
271,
26291-26295[Abstract/Free Full Text]
|
| 51.
|
Wiemann, S.,
Weil, B.,
Wellenreuther, R.,
Gassenhuber, J.,
Glassl, S.,
Ansorge, W.,
Bocher, M.,
Blocker, H.,
Bauersachs, S.,
Blum, H.,
Lauber, J.,
Dusterhoft, A.,
Beyer, A.,
Kohrer, K.,
Strack, N.,
Mewes, H. W.,
Ottenwalder, B.,
Obermaier, B.,
Tampe, J.,
Heubner, D.,
Wambutt, R.,
Korn, B.,
Klein, M.,
and Poustka, A.
(2001)
Genome Res.
11,
422-435[Abstract/Free Full Text]
|
| 52.
|
Ramesh, N.,
Anton, I. M.,
Hartwig, J. H.,
and Geha, R. S.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14671-14676[Abstract/Free Full Text]
|
| 53.
|
Vetterkind, S.,
Miki, H.,
Takenawa, T.,
Klawitz, I.,
Scheidtmann, K. H.,
and Preuss, U.
(2001)
J. Biol. Chem.
277,
87-95[Medline]
[Order article via Infotrieve]
|
| 54.
|
Guinamard, R.,
Aspenstrom, P.,
Fougereau, M.,
Chavrier, P.,
and Guillemot, J. C.
(1998)
FEBS Lett.
434,
431-436[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Kim, A. S.,
Kakalis, L. T.,
Abdul-Manan, N.,
Liu, G. A.,
and Rosen, M. K.
(2000)
Nature
404,
151-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Prehoda, K. E.,
Scott, J. A.,
Mullins, R. D.,
and Lim, W. A.
(2000)
Science
290,
801-806[Abstract/Free Full Text]
|
| 57.
|
Zhou, Z.,
Caron, E.,
Hartwieg, E.,
Hall, A.,
and Horvitz, H. R.
(2001)
Dev. Cell
1,
477-489[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Wu, Y. C.,
Tsai, M. C.,
Cheng, L. C.,
Chou, C. J.,
and Weng, N. Y.
(2001)
Dev. Cell
1,
491-502[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Cicmil, M.,
Thomas, J. M.,
Sage, T.,
Barry, F. A.,
Leduc, M.,
Bon, C.,
and Gibbins, J. M.
(2000)
J. Biol. Chem.
275,
27339-27347[Abstract/Free Full Text]
|
| 60.
|
Trigwell, S.,
Wood, L.,
and Jones, P.
(2000)
Biochem. Biophys. Res. Commun.
278,
440-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 61.
|
Lowell, C. A.,
Soriano, P.,
and Varmus, H. E.
(1994)
Genes Dev.
8,
387-398[Abstract/Free Full Text]
|
| 62.
|
Albert, M. L.,
Kim, J. I.,
and Birge, R. B.
(2000)
Nat. Cell Biol.
2,
899-905[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Ahn, S.,
Maudsley, S.,
Luttrell, L. M.,
Lefkowitz, R. J.,
and Daaka, Y.
(1999)
J. Biol. Chem.
274,
1185-1188[Abstract/Free Full Text]
|
| 64.
|
Henley, J. R.,
Krueger, E. W.,
Oswald, B. J.,
and McNiven, M. A.
(1998)
J. Cell Biol.
141,
85-99[Abstract/Free Full Text]
|
| 65.
|
Kavanaugh, W. M.,
Pot, D. A.,
Chin, S. M.,
Deuter-Reinhard, M.,
Jefferson, A. B.,
Norris, F. A.,
Masiarz, F. R.,
Cousens, L. S.,
Majerus, P. W.,
and Williams, L. T.
(1996)
Curr. Biol.
6,
438-445[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Yokouchi, M.,
Kondo, T.,
Sanjay, A.,
Houghton, A.,
Yoshimura, A.,
Komiya, S.,
Zhang, H.,
and Baron, R.
(2001)
J. Biol. Chem.
276,
35185-35193[Abstract/Free Full Text]
|
| 67.
|
Andoniou, C. E.,
Lill, N. L.,
Thien, C. B.,
Lupher, M. L., Jr.,
Ota, S.,
Bowtell, D. D.,
Scaife, R. M.,
Langdon, W. Y.,
and Band, H.
(2000)
Mol. Cell. Biol.
20,
851-867[Abstract/Free Full Text]
|
| 68.
|
Tsygankov, A. Y.,
Teckchandani, A. M.,
Feshchenko, E. A.,
and Swaminathan, G.
(2001)
Oncogene
20,
6382-6402[CrossRef][Medline]
[Order article via Infotrieve]
|
| 69.
|
Park, C.,
Choi, Y.,
and Yun, Y.
(1998)
Mol. Cell
8,
518-523
|
| 70.
|
Nimnual, A. S.,
Yatsula, B. A.,
and Bar-Sagi, D.
(1998)
Science
279,
560-563[Abstract/Free Full Text]
|
| 71.
|
Watanabe, S.,
Take, H.,
Takeda, K., Yu, Z. X.,
Iwata, N.,
and Kajigaya, S.
(2000)
Biochem. Biophys. Res. Commun.
278,
167-174[CrossRef][Medline]
[Order article via Infotrieve]
|
| 72.
|
Bear, J. E.,
Krause, M.,
and Gertler, F. B.
(2001)
Curr. Opin. Cell Biol.
13,
158-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 73.
|
Brown, M. T.,
Andrade, J.,
Radhakrishna, H.,
Donaldson, J. G.,
Cooper, J. A.,
and Randazzo, P. A.
(1998)
Mol. Cell. Biol.
18,
7038-7051[Abstract/Free Full Text]
|
| 74.
|
King, F. J., Hu, E.,
Harris, D. F.,
Sarraf, P.,
Spiegelman, B. M.,
and Roberts, T. M.
(1999)
Mol. Cell. Biol.
19,
2330-2337[Abstract/Free Full Text]
|
| 75.
|
Weng, Z.,
Thomas, S. M.,
Rickles, R. J.,
Taylor, J. A.,
Brauer, A. W.,
Seidel-Dugan, C.,
Michael, W. M.,
Dreyfuss, G.,
and Brugge, J. S.
(1994)
Mol. Cell. Biol.
14,
4509-4521[Abstract/Free Full Text]
|
| 76.
|
Krecic, A. M.,
and Swanson, M. S.
(1999)
Curr. Opin. Cell Biol.
11,
363-371[CrossRef][Medline]
[Order article via Infotrieve]
|
| 77.
|
Martinez-Quiles, N.,
Rohatgi, R.,
Anton, I. M.,
Medina, M.,
Saville, S. P.,
Miki, H.,
Yamaguchi, H.,
Takenawa, T.,
Hartwig, J. H.,
Geha, R. S.,
and Ramesh, N.
(2001)
Nat. Cell Biol.
3,
484-491[CrossRef][Medline]
[Order article via Infotrieve]
|
| 78.
|
Ohta, S.,
Mineta, T.,
Kimoto, M.,
and Tabuchi, K.
(1997)
Biochem. Biophys. Res. Commun.
237,
307-312[CrossRef][Medline]
[Order article via Infotrieve]
|
| 79.
|
Dutcher, S. K.
(2001)
Curr. Opin. Cell Biol.
13,
49-54[CrossRef][Medline]
[Order article via Infotrieve]
|
| 80.
|
Hartmann, A. M.,
Nayler, O.,
Schwaiger, F. W.,
Obermeier, A.,
and Stamm, S.
(1999)
Mol. Biol. Cell
10,
3909-3926[Abstract/Free Full Text]
|
| 81.
|
Lang, V.,
Semichon, M.,
Michel, F.,
Brossard, C.,
Gary-Gouy, H.,
and Bismuth, G.
(1999)
J. Immunol.
162,
7224-7232[Abstract/Free Full Text]
|
| 82.
|
Shen, Z.,
Batzer, A.,
Koehler, J. A.,
Polakis, P.,
Schlessinger, J.,
Lydon, N. B.,
and Moran, M. F.
(1999)
Oncogene
18,
4647-4653[CrossRef][Medline]
[Order article via Infotrieve]
|
| 83.
|
Huang, S.
(2000)
J. Struct. Biol.
129,
233-240[CrossRef][Medline]
[Order article via Infotrieve]
|
| 84.
|
Kirsch, K. H.,
Georgescu, M. M.,
Ishimaru, S.,
and Hanafusa, H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
6211-6216[Abstract/Free Full Text]
|
| 85.
|
Lehtonen, S.,
Ora, A.,
Olkkonen, V. M.,
Geng, L.,
Zerial, M.,
Somlo, S.,
and Lehtonen, E.
(2000)
J. Biol. Chem.
275,
32888-32893[Abstract/Free Full Text]
|
| 86.
|
Lo, Y. F.,
Chen, T. C.,
Chen, S. C.,
and Chao, C. C.
(2000)
Breast Cancer Res. Treat.
60,
259-266[CrossRef][Medline]
[Order article via Infotrieve]
|
| 87.
|
Vogel, L. B.,
and Fujita, D. J.
(1993)
Mol. Cell. Biol.
13,
7408-7417[Abstract/Free Full Text]
|
| 88.
|
Katso, R.,
Okkenhaug, K.,
Ahmadi, K.,
White, S.,
Timms, J.,
and Waterfield, M. D.
(2001)
Annu. Rev. Cell Dev. Biol.
17,
615-675[CrossRef][Medline]
[Order article via Infotrieve]
|
| 89.
|
Sanzenbacher, R.,
Kabelitz, D.,
and Janssen, O.
(1999)
J. Immunol.
163,
3143-3152[Abstract/Free Full Text]
|
| 90.
|
Judd, B. A.,
and Koretzky, G. A.
(2001)
Oncogene
20,
6291-6299[CrossRef][Medline]
[Order article via Infotrieve]
|
| 91.
|
Krantz, S.,
Salazar, R.,
Brandt, R.,
Kellermann, J.,
and Lottspeich, F.
(1995)
Biochim. Biophys. Acta
1266,
109-112[Medline]
[Order article via Infotrieve]
|
| 92.
|
Das, B. K.,
Xia, L.,
Palandjian, L.,
Gozani, O.,
Chyung, Y.,
and Reed, R.
(1999)
Mol. Cell. Biol.
19,
6796-6802[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Tsuboi and J. Meerloo
Wiskott-Aldrich Syndrome Protein Is a Key Regulator of the Phagocytic Cup Formation in Macrophages
J. Biol. Chem.,
November 23, 2007;
282(47):
34194 - 34203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Vincent, I. Maridonneau-Parini, C. Le Clainche, P. Gounon, and A. Labrousse
Activation of p61Hck Triggers WASp- and Arp2/3-dependent Actin-comet Tail Biogenesis and Accelerates Lysosomes
J. Biol. Chem.,
July 6, 2007;
282(27):
19565 - 19574.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Chellaiah, D. Kuppuswamy, L. Lasky, and S. Linder
Phosphorylation of a Wiscott-Aldrich Syndrome Protein-associated Signal Complex Is Critical in Osteoclast Bone Resorption
J. Biol. Chem.,
March 30, 2007;
282(13):
10104 - 10116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Yokoyama, J. Lougheed, and W. T. Miller
Phosphorylation of WASP by the Cdc42-associated Kinase ACK1: DUAL HYDROXYAMINO ACID SPECIFICITY IN A TYROSINE KINASE
J. Biol. Chem.,
December 23, 2005;
280(51):
42219 - 42226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Itoh, T. Hirose, N. Takata, K. Nishiwaki, M. Koga, Y. Ohshima, and M. Okada
SRC-1, a non-receptor type of protein tyrosine kinase, controls the direction of cell and growth cone migration in C. elegans
Development,
December 1, 2005;
132(23):
5161 - 5172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bogdan, O. Grewe, M. Strunk, A. Mertens, and C. Klambt
Sra-1 interacts with Kette and Wasp and is required for neuronal and bristle development in Drosophila
Development,
August 15, 2004;
131(16):
3981 - 3989.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Namekata, Y. Enokido, K. Iwasawa, and H. Kimura
MOCA Induces Membrane Spreading by Activating Rac1
J. Biol. Chem.,
April 2, 2004;
279(14):
14331 - 14337.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. M. Grimsley, J. M. Kinchen, A.-C. Tosello-Trampont, E. Brugnera, L. B. Haney, M. Lu, Q. Chen, D. Klingele, M. O. Hengartner, and K. S. Ravichandran
Dock180 and ELMO1 Proteins Cooperate to Promote Evolutionarily Conserved Rac-dependent Cell Migration
J. Biol. Chem.,
February 13, 2004;
279(7):
6087 - 6097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Shivakrupa, V. Radha, Ch. Sudhakar, and G. Swarup
Physical and Functional Interaction between Hck Tyrosine Kinase and Guanine Nucleotide Exchange Factor C3G Results in Apoptosis, Which Is Independent of C3G Catalytic Domain
J. Biol. Chem.,
December 26, 2003;
278(52):
52188 - 52194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Bogdan and C. Klambt
Kette regulates actin dynamics and genetically interacts with Wave and Wasp
Development,
September 15, 2003;
130(18):
4427 - 4437.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|